Resistant HIV quickly hides in infants' cells

Mother-to-child transmission of HIV is an important factor in the AIDS pandemic, although important strides have been made in limiting transmission with antiviral drug therapies before, during, and following birth. In the last few decades the rate of mother-to-child transmission of HIV in the United States has been reduced from 25 percent to its current rate of less than 2 percent. However, the transmission of drug-resistant strains of HIV from mother to child is still a problem, and much is unknown concerning how such transmission affects the responses of infants to various drug treatments.

The study, conducted by Deborah Persaud, MD, of Johns Hopkins University School of Medicine and colleagues working throughout the United States, analyzed HIV-infected infants less than six months of age enrolled in a large, multi-center clinical trial covering 10 states.

Their results showed that five of 21 HIV-positive infants were infected with drug-resistant HIV transmitted from their mothers—a surprisingly high figure. Of those five, four were resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs), a common class of antiretroviral drug used to treat HIV infection and to prevent mother-to-child transmission. All had uncommon drug-resistance mutations that some resistance tests would miss.

Earlier studies looking at infants treated with antiretrovirals in an unsuccessful attempt to prevent mother-to-child transmission found the virus quickly developed resistance, but levels of resistant virus declined over time to undetectable levels. In the current study, however, researchers found these resistant viruses quickly took up residence in inactive T cells, from where they could later launch an attack that NNRTIs could not stop. The news was not all bad: a different class of antiretroviral drugs, protease inhibitors (PIs), was effective in controlling HIV viral load and NNRTI-resistant virus strains for all infants studied.

These findings have important implications when it comes to choosing among available treatments. As Persaud summarized, "The initial transmitted drug-resistant virus will likely never be cleared from that infant with currently available treatments. However, it is important to point out that because PIs are the first-line drugs used to treat HIV infection in infants in the United States, PI-containing treatment was still effective in controlling the NNRTI-resistant virus in the infants in this study. As long as you do not use NNRTI-based treatment in these infants, you avoid applying pressure that allows drug-resistant HIV to flourish."

The study concluded that it is important to consider drug-resistance testing as a part of the initial evaluation of newly HIV-infected infants so that appropriate choices can be made when considering possible treatments, especially since PIs are not used worldwide as first-line therapy. Such testing must be paired with further studies on available and new therapies. As Persaud remarked, "It is important to fully understand the extent to which the persistent drug-resistant virus affects whether those drugs can be reused within the child’s lifetime.… This is a critical question and an area of intense investigation, especially in light of the high rates of antiretroviral drug resistance occurring in infants in low-income countries who received a single dose of an NNRTI for prevention of mother-to-child transmission, and for whom treatment options are few."

In an accompanying editorial, Paul A. Krogstad, MD, of the David Geffen School of Medicine at UCLA, noted that global elimination of pediatric AIDS will require not only prevention of mother-to-child transmission but also development of new antiretroviral agents for pediatric use, particularly against highly resistant infection. "There is also a need for new and widely accessible methods for detecting HIV infection in infants, whether resistant or not," he pointed out, "since transplacental transfer of maternal antibodies precludes the use of antibody detection methods." Affordable techniques also are necessary to reliably detect resistant HIV in less affluent areas of the world.

"FAST FACTS":

-- Five of 21 HIV-positive infants in this study were infected with drug-resistant HIV transmitted from their mothers.
-- These drug-resistant strains in quickly took up residence in inactive T cells, from where they could later launch an attack that NNRTIs could not stop. Protease inhibitors were still effective, however.
-- These results suggest that drug resistance testing of viruses from HIV infected infants before treatment should be implemented wherever feasible.

Source: Infectious Diseases Society of America

New study finds HIV drug can persist in mothers' milk, increasing risk to them and their babies
A drug commonly used in the developing world to prevent transmission of HIV from mother to child persists in the breast milk and blood of the mothers, putting them and their babies at risk for developing drug-resistant strains of the virus, according to researchers at the Stanford University School of Medicine.
Early cessation of breastfeeding by HIV+ women in poor countries and child survival
A new study by researchers from Columbia University's Mailman School of Public Health addresses one of the most challenging issues in infant health and preventing mother-to-child HIV transmission in poor countries. In these settings, HIV-infected mothers had been advised that for the best outcome for their infants, they should exclusively breast-feed, followed by a rapid weaning four to six months after birth.
Infant formula blocks HIV transmission via breastfeeding
Acquired Immune Deficiency Syndrome (AIDS) is a global epidemic threatening the lives of millions of people. Because there is no known cure, prevention of the transmission of the virus that causes AIDS, the Human Immunodeficiency Virus (HIV), is critical for controlling the disease.
Extended infant antiretroviral prophylaxis reduces HIV risk during breastfeeding
In many resource-poor countries, infants born to mothers with HIV receive a single dose of nevirapine (NVP) and a one-week dose of zidovudine (ZDV) to prevent transmission of HIV from the mother to her newborn. The results of a randomized trial led by researchers at the Johns Hopkins Bloomberg School of Public Health and the University of Malawi College of Medicine found that extending the routine antiretroviral regimen can significantly reduce the risk of mother-to-child HIV transmission. The study is available in the June 4 online edition of New England Journal of Medicine and will appear in the June 10 print edition.
Breastfeeding now safer for infants of HIV-infected mothers
An antiretroviral drug already in widespread use in the developing world to prevent the transmission of HIV from infected mothers to their newborns during childbirth has also been found to substantially cut the risk of subsequent HIV transmission during breast-feeding.
Circumcision doesn't reduce sexual satisfaction and performance, says study of 4,500 men
More than 98 per cent of men who are circumcised can enjoy the same levels of sexual satisfaction and performance as men who are not, according to a study of nearly 4,500 males published in the January issue of the UK-based urology journal BJU International.
Study shows what works in treating HIV-infected African children
Providing HIV combination antiretroviral drug therapy is key to saving the lives of African children infected with the disease.
Mother's milk a gift that keeps on giving
Extensive medical research shows that mothers’ milk satisfies babies’ nutritional needs far better than any manufactured infant formula. It also protects babies against many common infectious diseases and certain inflammatory diseases, and probably helps lower the risk of a child later developing diabetes, lymphoma and some types of leukemia.

Resistant HIV quickly hides in infants' cells

Related stories:

News discussion: